Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents

Completed · Phase 2

Conditions studied: Peripheral Artery Disease, Peripheral Vascular Disease

In brief

The objective of this study is to separately demonstrate the safety and efficacy of BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of femoro-popliteal lesions, located in the native superficial femoral artery (SFA) or proximal popliteal artery (PPA), while the Astron stent will be used for the treatment of the common or external iliac artery lesions.

Key facts

Study ID

NCT01319812

Run by

Biotronik, Inc.

People needed

463

Starts

2011-07-01

Expected to finish

2017-09-07

Last updated by the study team

2019-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To support the objectives of this study, the following initial inclusion criteria must be met for a subject to be enrolled and considered for the index procedure:
• Age ≥ 18 years
• Willingness to comply with study follow-up requirements
• Candidate for PTA
• Life-style limiting claudication or rest pain with an ABI ≤ 0.9 (resting or exercise). Thigh brachial index (TBI) may be used / performed if ABI is inadequate.
• Written informed consent
• For a subject to receive an investigational stent, the following procedure-related criteria must be met:
• One de novo, restenotic or occluded lesion representing a femoro-popliteal or iliac indication OR Two de novo, restenotic or occluded lesions representing one femoro-popliteal indication and one iliac indication on contralateral limbs - (i.e. one lesion per limb)
• Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion
• Subjects with bilateral, SFA/PPA disease (i.e. one SFA/PPA lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral SFA/PPA intervention may be performed at the time of the index procedure (prior to treatment of study lesion); however, the use of an investigational treatment is prohibited. If the contralateral SFA/PPA intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the contralateral intervention is prohibited.
• Subjects with bilateral, iliac disease (i.e. one iliac lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral iliac intervention may be performed at the time of the index procedure; however, the use of an investigational treatment is prohibited. If the contralateral iliac intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the subsequent contralateral intervention is also prohibited.
• Femoro-popliteal lesions must be located at least 1 cm distal to the profunda femoris artery and at least 3 cm above the knee joint (radiographic joint space)
• Iliac lesions must be located only in either the common or external iliac artery
• Lesions must be treatable with a maximum of two stents
• Angiographic evidence of ≥ 70% stenosis or occlusion (operator visual assessment)
• Lesion length ≤ 190 mm (if de novo or restenotic) or ≤ 100 mm (if occluded)
• Target vessel reference diameter: 2.5 to 6 mm (SFA/PPA) or 6 to 9 mm (iliac arteries) by visual estimate
• Angiographic evidence of patent SFA and PPA (iliac indication) and angiographic evidence of at least one distal vessel runoff to the foot (both femoro-popliteal and iliac indications). Patent is defined as < 50% stenosis.
• For SFA/PPA intervention, a significant stenosis (> 70%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) just prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.

You may not qualify if…

• To support the objectives of this study, the following initial exclusion criteria must not be present for a subject to be enrolled:
• Subjects pregnant or planning to become pregnant during the course of the study
• Life expectancy of less than one year
• Rutherford-Becker category 5 or 6. Subjects with ulcers caused by venous disease may be enrolled in the study.
• Previously stented lesion(s) in the target vessel
• Target lesion(s) received previous treatment within 30 days prior to enrollment
• Prior peripheral vascular bypass surgery involving the target limb(s)
• Thrombophlebitis or deep vein thrombosis within the past 30 days
• Known allergy to nitinol (nickel and/or titanium)
• Participation in any other clinical investigational device or drug study. Subjects may be concurrently enrolled in a post-market study, as long as the post-market study device, drug or protocol does not interfere with the investigational treatment or protocol of this study.
• Previous stroke or transient ischemic attack within the last three months prior to enrollment
• Previous coronary or peripheral bypass surgery (non-target limb) within 30 days prior to enrollment
• Intolerance to contrast agents that cannot be medically managed and/or intolerance to anti-platelet, anti-coagulant or thrombolytic medications
• Refuses blood transfusions
• Any medical condition, that in the opinion of the investigator, poses an unacceptable risk for implant of a stent according to the study indications
• For a subject to receive an investigational stent the following procedure-related criteria must not be present:
• INR ≥ 1.6
• Concomitant renal failure with serum creatinine level > 2.5 mg/dL
• Unresolved neutropenia (white blood cell count < 3,000 / µL) or thrombocytopenia (platelet count < 80,000 / µL) at the time of the index procedure
• Unresolved bleeding disorder (INR ≥ 1.6) at the time of the index procedure
• Presence of other ipsilateral, arterial lesions distal to the target lesion requiring treatment within 30 days of the index procedure (either before or after) or at the time of the index procedure
• Additional percutaneous interventional procedures (cardiac and/or peripheral) planned within 30 days after the index procedure
• Presence of a complication following pre-dilation of target lesion
• Presence of a target vessel/lesion that is excessively tortuous or calcified or is adjacent to an acute thrombus that is unresponsive to anti-thrombotic therapies
• Target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion

Where it is running

• Study site — Fremont, California, United States
• Study site — New Haven, Connecticut, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Rockford, Illinois, United States
• Study site — Munster, Indiana, United States
• Study site — Houma, Louisiana, United States
• Study site — Lansing, Michigan, United States
• Study site — Saginaw, Michigan, United States
• Study site — Wyoming, Michigan, United States
• Study site — Ypsilanti, Michigan, United States
• Study site — Tupelo, Mississippi, United States
• Study site — Kansas City, Missouri, United States
• Study site — Ridgewood, New Jersey, United States
• Study site — New York, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Gastonia, North Carolina, United States
• Study site — High Point, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Toledo, Ohio, United States
• Study site — Toledo, Ohio, United States
• Study site — Camp Hill, Pennsylvania, United States
• Study site — Doylestown, Pennsylvania, United States
• Study site — Langhorne, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.